This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Cedric L Hugelshofer: Innovator in Pharmaceutical Chemistry
Introduction
Cedric L Hugelshofer is a notable inventor based in Oakland, CA. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds aimed at treating various metabolic and cognitive disorders.
Latest Patents
Hugelshofer holds a patent for the "Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors." This patent includes compounds of formula I and their pharmaceutically acceptable salts, esters, and prodrugs. These compounds serve as DGAT2 inhibitors and are designed to treat conditions such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, and cardiorenal diseases like chronic kidney diseases and heart failure.
Career Highlights
Hugelshofer is currently employed at Merck Sharp & Dohme LLC, where he continues to advance his research and development efforts. His work has led to the creation of innovative pharmaceutical compositions and methods for utilizing these compounds in clinical settings.
Collaborations
Throughout his career, Hugelshofer has collaborated with esteemed colleagues, including Jianming Bao and Emma Helen Southgate. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Cedric L Hugelshofer's contributions to pharmaceutical chemistry and his innovative patent work exemplify the impact of dedicated inventors in the field. His ongoing research continues to pave the way for new treatments for complex health conditions.